EUCERD (The European Union Committee of Experts on Rare Diseases). Recommendation of the European Union committee of experts on rare diseases to the European Commission and the Member States on improving informed decisions based on the clinical added value of orphan medicinal products (CAVOMP) information flow. 2012. http://ec.europa.eu/health/rare_diseases/docs/eucerd_cavomp_annex_en.pdf. Accessed 06 Sep 2016.
Google Scholar
European Commission. Inventory of Union and Member State incentives to support research into, and the development and availability of, orphan medicinal products. 2015. http://ec.europa.eu/health/files/orphanmp/doc/orphan_inv_cwd_20160126.pdf. Accessed 07 Sep 2016.
Google Scholar
European Commission. Orphan medicinal products. 2016. http://ec.europa.eu/health/human-use/orphan-medicines/index_en.htm. Accessed 06 Sep 2016.
Google Scholar
Dupont A, Van Wilder P. Access to orphan drugs despite poor quality of clinical evidence. Br J Clin Pharmacol. 2011;71(4):488–96.
Article
PubMed
PubMed Central
Google Scholar
Gutierrez L, Patris J, Hutchings A, Cowell W. Principles for consistent value assessment and sustainable funding of orphan drugs in Europe. Orphanet J Rare Dis. 2015;10:53.
Article
PubMed
PubMed Central
Google Scholar
Barham L. Orphan medicines: special treatment required? 2012. http://socialwelfare.bl.uk/subject-areas/services-activity/health-services/2020health/147277orphan_medicines_2012.pdf. Accessed 06 Sep 2016.
Google Scholar
Gammie T, Lu C, Babar ZD. Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries. PLoS One. 2015;10(10):e0140002.
Article
PubMed
PubMed Central
Google Scholar
Garau M, Mestre-Ferrandiz J. Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries. 2009. https://www.ohe.org/publications/access-mechanisms-orphan-drugs-comparative-study-selected-european-countries. Accessed 06 Sep 2016.
Google Scholar
EURORDIS. Inventory of access and prices of orphan drugs across Europe: a collaborative work between National Alliances on Rare Diseases & EURORDIS. 2010. http://img.eurordis.org/newsletter/pdf/mar-2011/ERTC_13122010_YLeCam_Final.pdf. Accessed 07 Sep 2016.
Google Scholar
Morel T, Arickx F, Befrits G, Siviero P, van der Meijden C, Xoxi E, et al. Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries. Orphanet J Rare Dis. 2013;8:198.
Article
PubMed
PubMed Central
Google Scholar
Van den Aardweg S. HTA of orphan drugs across six countries: fair, flawed or failing? Euro Observer. 2010;12(4):14–7.
Google Scholar
Kesselheim A, Myers J, Avorn J. Characteristics of Clinical Trials to Support Approval of Orphan vs Nonorphan Drugs for Cancer. JAMA. 2011;305(22):2320–6.
Article
CAS
PubMed
Google Scholar
EMA (European Medicine Agency). Orphan designation. 2016. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000029.jsp. Accessed 8 Dec 2016.
Google Scholar
Simoens S, Picavet E, Dooms M, Cassiman D, Morel T. Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum. Appl Health Econ Health Policy. 2013;11:1–3.
Article
PubMed
Google Scholar
Drummond L, Towse A. Orphan drugs policies: a suitable case for treatment. Eur J Health Econ. 2014;15:335–40.
Article
PubMed
Google Scholar
Schey C, Milanova T, Hutchings A. Estimating the budget impact of orphan medicines in Europe: 2010–2020. Orphanet J Rare Dis. 2011;6:62.
Article
PubMed
PubMed Central
Google Scholar
Rollet P, Lemoine A, Dunoyer M. Sustainable rare diseases business and drug access: no time for misconceptions. Orphanet J Rare Dis. 2013;8:109.
Article
PubMed
PubMed Central
Google Scholar
Tordrup D, Tzouma V, Kanavos P. Orphan drug considerations in Health Technology Assessment in eight European countries. Rare Diseases and Orphan Drugs: An International Journal of Public Health. 2014;1(3):86–97.
Google Scholar
Australian Government - Department of Health. Life saving drugs program criteria and conditions. 2016. http://www.health.gov.au/internet/main/publishing.nsf/Content/lsdp-criteria. Accessed 16 Sep 2016.
Nicod E. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries. Eur J Health Econ. 2016 [Epub ahead of print].
Sussex J, Rollet P, Garau M, Schmitt C, Kent A, Hutchings A. Multi-Criteria Decision Analysis to Value Orphan Medicines. 2013. https://www.ohe.org/publications/multi-criteria-decision-analysis-value-orphan-medicines. Accessed 06 Sep 2016.
Google Scholar
Krüger L, Tamminga J, Wijnen B, Hiligsmann M, Evers S. An European overview of the future changes in evidence requirements for the reimbursement of orphan drugs A stakeholder analysis. Value Health. 2014;17(3):A236. https://www.ispor.org/research_pdfs/46/pdffiles/PSY72.pdf.
Grubert N. How will the Pharmadialog change the AMNOG and market access in Germany? 2016. https://www.linkedin.com/pulse/how-pharmadialog-change-amnog-market-access-germany-neil-grubert. Accessed 08 Sep 2016.
Google Scholar
Palaska C, Hutchings A. Value Assessment and Pricing Frameworks for Rare Disease Treatments: New Approaches From The Literature. Value Health. 2015;18(7):A678.
Article
CAS
PubMed
Google Scholar
European Commission. Transparent value framework (Platform on access to medicines in Europe - Working Group on Mechanism of coordinated access to orphan medicinal products). 2014. http://ec.europa.eu/DocsRoom/documents/7631?locale=fr. Accessed 14 Sep 2016.
Google Scholar
Hughes-Wilson W, Palma A, Schuurman A, Simoens S. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis. 2012;7:74.
Article
PubMed
PubMed Central
Google Scholar
Fedyaeva V, Omelyanovskiy V, Rebrova O, Khan NN, Petrovskaya E. MCDA approach to ranking rare diseases in Russia: preliminary results. Value Health. 2014;17(7):A539.
Article
CAS
PubMed
Google Scholar
Schey C, Connolly M. Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugs. Value Health. 2014;17(7):A556.
Article
CAS
PubMed
Google Scholar
Paulden M, Stafinski T, Menon D, McCabe C. Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework. Pharmacoeconomics. 2015;33:255–69.
Article
PubMed
Google Scholar
Wagner M, Khoury H, Willet J, Rindress D, Goetghebeur M. Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation. Pharmacoeconomics. 2016;34:285–301.
Article
PubMed
Google Scholar
Kanavos P, Angelis A. Multiple Criteria Decision Analysis for Value Based Assessment of New Medical Technologies: A Conceptual Framework. 2013. http://eprints.lse.ac.uk/51211/. Accessed 20 Sep 2016.
Google Scholar
Endrei D, Molics B, Ágoston I. ulticriteria Decision Analysis in the Reimbursement of New Medical Technologies: Real-World Experiences from Hungary. Value Health. 2014;17(4):487–9.
Article
PubMed
Google Scholar
Williams P, Mauskopf J, Lebiecki J, Kilburg A. Using multicriteria decision analysis during drug development to predict reimbursement decisions. J Mark Access Health Policy. 2014. doi:10.3402/jmahp.v2.25270.
Google Scholar
Wahlster P, Goetghebeur M, Schaller S, Kriza C, Kolominsky-Rabas P, EMN' NLECMT‘V. Exploring the perspectives and preferences for HTA across German healthcare stakeholders using a multi-criteria assessment of a pulmonary heart sensor as a case study. Health Res Policy Syst. 2015;13:24.
Article
PubMed
PubMed Central
Google Scholar
Cherny N, Dafni UKJ, Sobrero A, Zielinski C, de Vries E, Piccart M. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol. 2015;26:1547–73.
Article
CAS
PubMed
Google Scholar
Schnipper L, Davidson N, Wollins D, Tyne C, Blayney D, Blum D, et al. American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. J Clin Oncol. 2015;33(23):2563–77.
Article
PubMed
PubMed Central
Google Scholar
EURORDIS. The Voice of 12,000 Patients: Experiences and Expectations of Rare Disease Patients on Diagnosis and Care in Europe. 2009. http://www.eurordis.org/IMG/pdf/voice_12000_patients/EURORDISCARE_FULLBOOKr.pdf. Accessed 06 Sep 2016.
Google Scholar
de Vrueh R, Baekelandt E, de Haan J. World Health Organisation update on 2004 Background Paper, BP 6.19 Rare Diseases. 2013. http://www.who.int/medicines/areas/priority_medicines/BP6_19Rare.pdf. Accessed 08 Sep 2016.
Google Scholar
Schieppati A, Henter JI, Daina E, Aperia A. Why rare diseases are an important medical and social issue. Lancet. 2008;371:2039–41.
Article
PubMed
Google Scholar
EUCERD (The European Union Committee of Experts on Rare Diseases). Rare Diseases: addressing the need for specialised social services and integration into social policies. 2012. http://www.eucerd.eu/wp-content/uploads/2013/03/EJA_Specialised_Social_Services_Paper.pdf. Accessed 06 Sep 2016.
Google Scholar
Mazzucato M, Visonà Dalla Pozza L, Manea S, Minichiello C, Facchin P. A population-based registry as a source of health indicators for rare diseases: the ten-year experience of the Veneto Region’s rare diseases registry. Orphanet J Rare Dis. 2014;9:37.
Article
PubMed
PubMed Central
Google Scholar
EUCERD (The European Union Committee of Experts on Rare Diseases). Report on EUCERD guiding principles for social care in RD/draft of Expert Group Recommendations in the social field. 2015. http://www.eucerd.eu/wp-content/uploads/2016/03/EJADeliverable7.pdf. Accessed 06 Sep 2016.
Google Scholar
Paris V, Belloni A. Value in Pharmaceutical Pricing. OECD Health Working Papers. 2013. doi:10.1787/5k43jc9v6knx-en.
Article
Google Scholar
Schlander M, Garattini S, Holm S, Kolominsky-Rabas P, Nord E, Persson U, et al. Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders. J Comp Eff Res. 2014;3(4):399–422.
Article
PubMed
Google Scholar
Whitty J, Lancsar E, Rixon K, Golenko X, Ratcliffe J. A systematic review of stated preference studies reporting public preferences for healthcare priority setting. Patient. 2014;7(4):365–86.
Article
PubMed
Google Scholar
European Commission. Transparency Directive (Council Directive 89/105/EEC). 1989. https://ec.europa.eu/growth/sectors/healthcare/competitiveness/products-pricing-reimbursement/transparency-directive_en. Accessed 06 Sep 2016.
Google Scholar
Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011;6:42.
Article
PubMed
PubMed Central
Google Scholar
Douglas M, Wilcox E, Burgess M, Lynd L. Why orphan drug coverage reimbursement decision-making needs patient and public involvement. Health Policy. 2015;119(5):588–96.
Article
PubMed
Google Scholar
Solon C, Kanavos P. An analysis of HTA decisions for orphan drugs in Canada and Australia. Working Paper No: 42. 2015. http://www.lse.ac.uk/LSEHealthAndSocialCare/pdf/LSEHealthworkingpaperseries/LSEHWP42.pdf. Accessed 08 Sep 2016.
Google Scholar
Hughes D, Tunnage B, Yeo S. Drugs for exceptionally rare diseases: do they deserve special status for funding? QJM. 2005;98:829–36.
Article
CAS
PubMed
Google Scholar
Farrugia A, O’Mahony B, Cassar J. Health technology assessment and haemophilia. Haemophilia. 2012;18:152–7.
Article
CAS
PubMed
Google Scholar
Lantrès O. Pricing and Reimbursement of Medicinal Products in France. 2013. http://www.eucope.org/en/files/2013/03/Lantr%C3%A8s-Pricing-and-Reimbursement-of-Medicinal-Products-in-France.pdf. Accessed 06 Sep 2016.
Google Scholar
GKV-spitzenverband (German Federation of Health Insurance Funds). AMNOG - evaluation of new pharmaceutical. 2016. https://www.gkv-spitzenverband.de/english/statutory_health_insurance/amnog_evaluation_of_new_pharmaceutical/amnog_english.jsp. Accessed 06 Sep 2016.
Drummond M, Wilson D, Kanavos P, Ubel P, Rovira J. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care. 2007;23(1):36–42.
Article
PubMed
Google Scholar
Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S. A comparative study of European rare disease and orphan drug markets. Health Policy. 2010;97(2–3):173–9.
Article
PubMed
Google Scholar
Schlander M, Holm S, Nord E, Richardson J, Garattini S, Kolominsky-Rabas P, et al. Discussion Paper N°31. Position Paper: Towards Social Cost Value Analysis: The Need for New Approaches for Evaluating Drugs for Ultra-Rare Diseases (URDs). 2015. http://www.innoval-hc.com/discussion-papers.html. Accessed 06 Sep 2016.
Google Scholar
Vickers P. Challenges and opportunities in the treatment of rare diseases. 2013. http://www.ddw-online.com/therapeutics/p211490-challenges-and-opportunities-in-the-treatment-of-rare-diseases-spring-13.html. Accessed 08 Sep 2016.
Google Scholar
Sharma A, Jacob A, Tandon M, Kumar D. Orphan drug: Development trends and strategies. J Pharm Bioallied Sci. 2010;2(4):290–9.
Article
PubMed
PubMed Central
Google Scholar
NICE (The National Institute for Health and Care Excellence, England). Highly specialised technologies guidance. 2016. https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-highly-specialised-technologies-guidance. Accessed 06 Sep 2016.
Google Scholar
Onakpoya I, Spencer E, Thompson M, Heneghan C. Effectiveness, safety and costs of orphan drugs: an evidence-based review. BMJ Open. 2015;5:e007199.
Article
PubMed
PubMed Central
Google Scholar
NICE (The National Institute for Health and Care Excellence, England). Citizens council reports: ultra orphan drugs. 2004. https://www.nice.org.uk/Media/Default/Get-involved/Citizens-Council/Reports/CCReport04UltraOrphanDrugs.pdf. Accessed 19 Dec 2016.
Google Scholar
Desser A, Gyrd-Hansen D, Olsen J, Grepperud S, Kristiansen I. Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67. BMJ. 2010;341:c4715.
Article
PubMed
PubMed Central
Google Scholar
Liney W, Hughes D. Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross sectional survey of 4118 adults in Great Britain. Health Econ. 2013;8(22):948–64.
Article
Google Scholar
WHO (World Health Organization). Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research. 2015. http://www.euro.who.int/en/health-topics/Health-systems/health-technologies-and-medicines/publications/2015/access-to-new-medicines-in-europe-technical-review-of-policy-initiatives-and-opportunities-for-collaboration-and-research-2015. Accessed 04 Sep 2016.
Google Scholar
EUR-Lex Access to European Union law. Council Recommendation of 8 June 2009 on an action in the field of rare diseases (2009/C 151/02). 2009. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2009:151:0007:0010:EN:PDF. Accessed 09 Sep 2016.
Google Scholar
Facey K. Patient involvement in HTA: What added value? Pharmaceuticals Policy and Law. 2011;13(3–4):245–51.
Google Scholar
Gasson S, Bliss J, Jamal-Hanjani M, Krebs M, Swanton C, Wilcox M. The Value of Patient and Public Involvement in Trial Design and Development. Clin Oncol (R Coll Radiol). 2015;27(12):747–9.
Article
CAS
Google Scholar
Berglas S, Jutai L, MacKean G, Weeks L. Patients’ perspectives can be integrated in health technology assessments: an exploratory analysis of CADTH Common Drug Review. Res Involv Engagem. 2016;2:21.
Article
Google Scholar
Staley K, Doherty C. It’s not evidence, it’s insight: bringing patients’ perspectives into health technology appraisal at NICE. Res Involv Engagem. 2016;2:4.
Article
Google Scholar
NICE (The National Institute for Health and Care Excellence, England). Patient and public involvement policy. 2016. https://www.nice.org.uk/about/nice-communities/public-involvement/patient-and-public-involvement-policy. Accessed 07 Sep 2016.
Google Scholar
EUPATI (The European Patients’ Academy). Patient involvement in the HTA decision-making process. 2016. https://www.eupati.eu/health-technology-assessment/patient-involvement-in-the-hta-decision-making-process/. Accessed 07 Sep 2016.
Google Scholar
Griggs R, Batshaw M, Dunkle M, Gopal-Srivastava R, Kaye E, Krischer J, et al. Clinical research for rare disease: Opportunities, challenges, and solutions. Mol Genet Metab. 2009;96(1):20–6.
Article
CAS
PubMed
Google Scholar
Augustine E, Adams H, Mink J. Clinical Trials in Rare Disease: Challenges and Opportunities. J Child Neurol. 2013;28(9):1142–50.
Article
PubMed
PubMed Central
Google Scholar
Mullins D, Vandigo J, Zheng Z, Wicks P. Patient-Centeredness in the Design of Clinical Trials. Value Health. 2014;17(4):471–5.
Article
PubMed
PubMed Central
Google Scholar
Potter B, Khangura S, Tingley K, Chakraborty P, Little J. Translating rare-disease therapies into improved care for patients and families: what are the right outcomes, designs, and engagement approaches in health-systems research. Genet Med. 2016;18(2):117–23.
Article
PubMed
Google Scholar
Facey K, Granados A, Guyatt G, Kent A, Shah N, van der Wilt G, et al. Generating health technology assessment evidence for rare diseases. Int J Technol Assess Health Care. 2014;30(4):416–22.
Article
PubMed
Google Scholar
IRDiRC-EMA (The International Rare Diseases Research Consortium and European Medicine Agency). Preparatory Document for Joint Workshop on Small Population Clinical Trials Challenges in the Field of Rare Diseases (DRAFT). 2016. http://www.irdirc.org/wp-content/uploads/2016/01/SPCT_DraftDocument.pdf. Accessed 09 Sep 2016.
Google Scholar
NICE (The National Institute for Health and Care Excellence, England). Elosulfase alfa for treating mucopolysaccharidosis type IVA. Response to consultee and commentator comments on the draft remit, draft scope (pre-referral) and provisional matrix. 2014. https://www.nice.org.uk/guidance/HST2/documents/mucopolysaccharidosis-type-iva-elosulfase-alfa-id7449. Accessed 20 Sep 2016.
Google Scholar
NICE (The National Institute for Health and Care Excellence, England). Eculizumab for treating atypical haemolytic uraemic syndrome. 2015. https://www.nice.org.uk/guidance/hst1. Accessed 08 Sep 2016.
Google Scholar
EUPATI (The European Patients’ Academy). What is EUPATI? 2016. https://www.eupati.eu/what-is-eupati. Accessed 08 Dec 2016.
Google Scholar
HTAi (Health Technology Assessment International). For patients and patient groups. 2016. http://www.htai.org/interest-groups/patient-and-citizen-involvement/resources/for-patients-and-patient-groups.html. Accessed 15 Sep 2016.
Google Scholar
EMA (European Medicine Agency). CHMP Guideline on the scientific application and the practical arrangements necessary to implement EC 507/2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of EC 726/2004. 2006. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500004908.pdf. Accessed 04 Sep 2016.
Google Scholar
Ferrario A, Kanavos P. Managed entry agreements for pharmaceuticals: the European experience. 2013. http://eprints.lse.ac.uk/50513/1/__Libfile_repository_Content_Ferrario,%20A_Ferrario_Managed_%20entry_%20agreements_2013_Ferrario_Managed_%20entry_%20agreements_2013.pdf. Accessed 19 Dec 2016.
Google Scholar
EMA (European Medicine Agency). Adaptive pathways. 2016. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000601.jsp&mid=WC0b01ac05807d58ce. Accessed 09 Sep 2016.
EUCERD (The European Union Committee of Experts on Rare Diseases). EUCERD core recommendations on rare disease patient registration and data collection. 2013. http://www.eucerd.eu/wp-content/uploads/2013/06/EUCERD_Recommendations_RDRegistryDataCollection_adopted.pdf. Accessed 19 Dec 2016.
Google Scholar
EUnetHTA (European Network for Health Technology Assessment). Evidence Generation – on the road to standardisation along the life-cycle of health technology. 2016. http://www.eunethta.eu/news/evidence-generation-road-standardisation-along-life-cycle-health-technology. Accessed 09 Sep 2016.
Google Scholar
Field M, Berman R. The Ethical Conduct of Clinical Research Involving Children. 1st ed. Washington: The National Academies Press; 2004.
Google Scholar
Simon K, Partners Healthcare Insights. Beyond AIFA: Navigating the next phase of Italian market access negotiations. 2013. https://www.simon-kucher.com/sites/default/files/hci_fall2013_volumevii_issue3.pdf. Accessed 02 Sep 2016.
Google Scholar
Jönsson B, Wilking N. New cancer drugs in Sweden: Assessment, implementation and access. J Cancer Policy. 2014;2:45–62.
Article
Google Scholar
Adams B. Scotland creates fund for rare diseases. 2013. http://www.pharmatimes.com/news/scotland_creates_fund_for_rare_diseases_1004243. Accessed 09 Sep 2016.
Google Scholar
AIFA (Italian Medicines Agency). The independent research on drugs. 2016. http://www.agenziafarmaco.gov.it/en/content/independent-research-drugs. Accessed 09 Sep 2016.
Google Scholar
NHS England Cancer Drugs Fund Tram. Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drug Fund). A new deal for patients, taxpayers and industry. 2016. https://www.england.nhs.uk/wp-content/uploads/2013/04/cdf-sop.pdf. Accessed 19 Dec 2016.
Google Scholar
Rare Disease Task Force. Centre of References for rare diseases in Europe: State-of-the-art in 2006 and recommendations of the Rare Disease Task Force. 2006. http://ec.europa.eu/health/archive/ph_threats/non_com/docs/contribution_policy.pdf. Accessed 20 Sep 2016.
Google Scholar
Kleijnen S, Toenders W, de Groot F, Huic M, George E, Wieseler B, et al. European collaboration on relative effectiveness assessments: What is needed to be successful? Health Policy. 2015;119(5):569–76.
Article
PubMed
Google Scholar
Mestre-Ferrandiz J, Garau M, O'Neill P, Sussex J. Assessment of the Impact of Orphan Medicinal Products on the European Economy and Society. 2010. https://www.ohe.org/publications/assessment-impact-orphan-medicinal-products-european-economy-and-society. Accessed 19 Dec 2016.
Google Scholar